Explore 3 Stock Ideas & Industry Insights Download Free Report

News

European Natural Gas Rises to €67.5/MWh, Highest Since January 2023, on Iran Sanctions Threat

European natural gas prices rose more than 2% to €67.5 per megawatt-hour, the highest since January 2023, as investors awaited details of a US plan to economically isolate Iran that could further disrupt energy supplies from the Middle East.

Nitish Kishor | 24 August 2026

Gold Rises to $4,630 an Ounce, Highest Since Mid-May, on Debasement Trade

Gold rose to around $4,630 an ounce on Monday, extending last week's gains and reaching its highest level since mid-May, as concerns over US debt management and fiscal sustainability persisted following the Treasury's unexpected ramp-up in longer-dated debt buybacks.

Nitish Kishor | 24 August 2026

Silver Trades Above $69 an Ounce at Two-Month High on Debasement Trade

Silver traded above $69 an ounce on Monday, hovering at a two-month high, as concerns over USDebtmanagement and fiscal sustainability persisted after the Treasury unexpectedly ramped up buybacks of longer-dated government debt.

Nitish Kishor | 24 August 2026

Coal Prices Rise Above $131 a Ton on Firm Asian Energy Demand

Coal prices rose above $131 per ton in late August, reaching their highest level since early August, amid firm Asian energy demand and ongoing supply risks.

Nitish Kishor | 24 August 2026

Telix Pharmaceuticals (NASDAQ: TLX) Falls 9% Despite Strong 1H Revenue and EBITDA Growth

Telix Pharmaceuticals Limited (NASDAQ: TLX) shares closed down 9% at $11.33 despite reporting 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million.

Nitish Kishor | 24 August 2026

Seres Therapeutics (NASDAQ: MCRB) Swings to Q2 Net Profit on VOWST Gain

Seres Therapeutics, Inc. (NASDAQ: MCRB) pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit, primarily fueled by a $25 million gain tied to VOWST and reduced overhead.

Nitish Kishor | 24 August 2026

Decoy Therapeutics (NASDAQ: DCOY) Reports Widened Q2 Net Loss on Increased R&D Spending

Decoy Therapeutics reported a 148% expansion in Q2 net losses to $2.37 million, primarily attributed to intensified R&D investments following the IMP3ACT program merger and legacy expenditure.

Nitish Kishor | 24 August 2026

Senti Biosciences (NASDAQ: SNTI) Falls 11% on New Convertible Note Issuance

Senti Biosciences, Inc. (NASDAQ: SNTI) shares closed down 11% at $0.39 afterSubsidiarySenti Holdings finalized a $4 million senior secured convertible note issuance to Celadon Partners SPV 24.

Nitish Kishor | 24 August 2026

SELLAS Life Sciences (NASDAQ: SLS) Rises 15% on Reiterated Maxim Buy Rating

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) shares closed up 15% at $15.46 after Maxim reiterated its Buy rating and $30 price target, notably above the $27.50 market consensus.

Nitish Kishor | 24 August 2026

Telix Pharmaceuticals (NASDAQ: TLX) Reports 1H Revenue of $477 Million as EBITDA Surges 146%

Telix Pharmaceuticals Limited (NASDAQ: TLX) reported 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million, driven by robust product sales and a $40 million collaboration milestone from Regeneron.

Nitish Kishor | 24 August 2026
Support

Hi! How can we help you today?

Loading…